机构：长城证券 研究员：刘鹏/蔡航 事件：近期，固生堂发布公告：1）2025Q3，公司客户就诊人次总数为160.7万，同比增长约8.2%；2） 固生堂附属公司Gushengtang Singapore（新加坡固生堂）与DA ZHONG TANG PTE. LTD.（大中堂）的 股东签署股权转让合同，拟收购大中堂100%股权。 客户就诊人次总数保持稳健增长。根据公司公告，2025 年Q1、Q2、Q3，公司客户就诊人次总数分别为 121.0 万、153.7 万、160.7 万，分别同比增长12.7%、17.4%、8.2%。 持续回购注销公司股份，彰显公司长期发展信心，重视股东回报。根据iFind，2025 年初至今，公司累 计回购股份数量达1105.26 万股，回购金额共计约3.39 亿港元，回购均价约30.66 港元。根据固生堂投资 者关系，2025 年10月，公司持续股份回购，10 月合计回购约421.76 万股，回购金额达1.27 亿港元。同 时，公司已于近期完成注销444.61 万股。根据公司公告，2025 年8 月29 日，公司董事会决议行使回购 授权，拟于公开市场回购价值最多3 亿港元的股份。2025 ...

公司研究 出海并购加速，回购加码彰显发展信心 ——固生堂（2273.HK）事件点评 要点 2025 年 11 月 18 日 事件：1）近期，公司公告附属公司 Gushengtang Singapore 于 2025 年 11 月 16 日与大中堂（DA ZHONG TANG PTE. LTD.）股东订立股权转协议，拟收购 大中堂 100%股权及全部相关权益。2）近期，公司董事会再次决议行使回购授 权，拟新增最多不超过 3 亿港元的回购额度。 点评： 出海并购步伐加快，业务扩张加速。此次对大中堂的收购是继今年 10 月与新 加坡数字医疗平台 1doc 达成战略合作后，固生堂在海外市场实现的又一重要 战略部署，标志着固生堂中医出海战略进入加速落地阶段。大中堂品牌在新加 坡运营 14 家中医门诊部，覆盖多个核心商圈及居民社区，拥有成熟的本地化服 务能力与高度信赖的用户基础。今年以来，固生堂持续加快中医药出海步伐， 采取"并购+合作+自建"三轮驱动策略，积极拓展新加坡市场。对大中堂收购 完成后，固生堂将新增运营 14 家门诊机构，有助于公司快速构建在新加坡的规 模化服务网络，提升区域市场覆盖与运营协同效应。公司持续推 ...

Core Insights - Gushengtang Singapore, a subsidiary of Gushengtang, signed a share transfer agreement to acquire 100% equity of Dazhong Tang PTE. LTD., marking a significant step in the company's overseas expansion strategy in traditional Chinese medicine [1][2] - Dazhong Tang is a major player in Singapore's traditional Chinese medicine sector, operating 14 clinics and possessing a strong local service capability and user trust [1] - The acquisition will enhance Gushengtang's overall revenue by consolidating Dazhong Tang's financial performance into its financial statements [1] Strategic Developments - Gushengtang is accelerating its international expansion in traditional Chinese medicine through a "merger + cooperation + self-built" strategy, particularly focusing on the Singapore market [2] - The recent strategic partnership with 1doc, a digital healthcare platform, involves establishing a joint venture where Gushengtang holds a 70% stake, allowing for the integration of traditional Chinese medicine services within 1doc's existing clinic network [2] - Following the acquisition of Dazhong Tang, Gushengtang will add 14 new clinics, enhancing its operational scale and market coverage in Singapore [2] Long-term Growth Potential - Gushengtang's multi-faceted approach to overseas expansion demonstrates a clear strategic plan and execution capability, aiming to integrate traditional Chinese medicine services internationally while adapting to local markets [2] - The company's dual strategy of deepening domestic operations while accelerating international growth is expected to create new growth opportunities and strengthen its leading position in the global traditional Chinese medicine sector [2]

Core Viewpoint - The company, Guoshengtang (02273), is expected to have strong earnings growth, with projected net profits for 2025-2027 of 400 million, 518 million, and 664 million yuan, representing year-on-year increases of 30.5%, 29.4%, and 28.2% respectively. The current stock price corresponds to PE ratios of 15.8, 12.2, and 9.5 for 2025-2027. A target PE of 20 times for 2026 suggests a target stock price of 49.09 HKD, maintaining a "strong buy" rating [1]. Group 1: Business Expansion - Since July 2025, the company has added 4 new branches through acquisitions, increasing the total number of branches to 87, enhancing regional service capabilities [2]. - The acquisition of Shenzhen Tianyuan Hospital is significant for integrating medical insurance, as it allows the company to access insurance coordination in Shenzhen, improving its competitive edge in the market [2]. - The acquisition of Tianjin Ping An Clinic marks the company's entry into the fourth largest traditional Chinese medicine market in China, opening new revenue opportunities in the Beijing-Tianjin-Hebei region [2]. Group 2: International Collaboration - On October 22, the company entered a strategic partnership with Singapore's 1doc to establish a joint venture, with the company holding a 70% stake and managing operations. This collaboration aims to leverage 1doc's established clinic network in Singapore for rapid scaling and efficient patient conversion [2]. Group 3: Share Buyback Program - The company has actively engaged in share buybacks, reflecting management's confidence in long-term value. Since September 1, 2025, it has conducted 42 buyback transactions totaling 8.14 million shares, with an investment of approximately 247 million HKD [3]. - On November 6, 2025, the board approved an additional buyback authorization of up to 300 million HKD, bringing the total buyback plan to a record high of 600 million HKD since the company's listing [3].

Core Viewpoint - The company, Guoshengtang (02273), shows strong certainty in profit growth, with projected net profits for 2025-2027 expected to increase by 30.5%, 29.4%, and 28.2% respectively, leading to a target stock price of HKD 49.09 based on a 20x PE ratio for 2026 [1][2] Group 1: Financial Projections - The projected net profits for Guoshengtang are estimated at 400 million, 518 million, and 664 million yuan for 2025, 2026, and 2027 respectively [1] - The corresponding PE ratios for 2025-2027 are 15.8, 12.2, and 9.5 times [1] Group 2: Strategic Acquisitions - Guoshengtang has acquired four new branches since July 2025, increasing the total to 87 branches, enhancing regional service capabilities [2] - The acquisition of Shenzhen Tianyuan Hospital is significant for integrating with medical insurance, enhancing competitive advantage in the Shenzhen market [2] - The acquisition of Tianjin Ping An Clinic allows entry into the fourth largest traditional Chinese medicine market in China, expanding growth opportunities in the Beijing-Tianjin-Hebei region [2] Group 3: International Expansion - A strategic partnership with Singapore's 1doc will establish a joint venture, with Guoshengtang holding 70% ownership, facilitating rapid scaling and patient conversion in Singapore [2] Group 4: Share Buyback Program - The company has actively engaged in share buybacks, with 42 buyback instances totaling 8.14 million shares and an investment of approximately 247 million HKD since September 1, 2025 [3] - The board has approved an additional buyback authorization of up to 300 million HKD, bringing the total buyback plan to a record 600 million HKD [3]

Core Viewpoint - Guosheng Securities has adjusted the profit forecast for Gushengtang (02273), expecting revenue and net profit growth from 2025 to 2027, maintaining a "Buy" rating for the company [1][2]. Financial Performance - Expected revenue for 2025, 2026, and 2027 is 3.27 billion, 3.94 billion, and 4.77 billion yuan, representing year-on-year growth of 8%, 21%, and 21% respectively [1]. - Expected net profit attributable to shareholders for the same years is 415 million, 529 million, and 661 million yuan, with year-on-year growth of 35%, 27%, and 25% respectively [1]. - Adjusted net profit forecasts are 460 million, 555 million, and 671 million yuan, with growth rates of 15%, 21%, and 21% [1]. Shareholder Returns - As of November 10, the company has paid out 420 million HKD in cash for interim dividends and buybacks [2]. - The company declared an interim dividend of 0.35 HKD per share, totaling 82.61 million HKD [2]. - The company has repurchased 11.05 million shares, accounting for approximately 4.68% of total share capital, with a repurchase amount of 339 million HKD [2]. Business Expansion - Since July 2025, the company has opened four new branches in Shenzhen, Tianjin, Nanjing, and Fuzhou, enhancing its service network [3]. - The Shenzhen Tianyuan Hospital is expected to improve the synergy of offline stores in the region, while the Tianjin branch marks the company's entry into the Tianjin market [3]. - The Nanjing and Fuzhou branches are part of the company's strategy to strengthen its existing service network in these cities [3]. International Expansion - The company has formed a strategic partnership with Singapore's 1doc to establish a joint venture, with Gushengtang holding 70% and managing operations [4]. - The joint venture will create dedicated TCM treatment areas within 1doc's existing clinic network, facilitating rapid scale-up [4]. - The company aims to establish 30 clinics in Singapore by the end of 2026, leveraging a combination of self-built, acquired, and cooperative models [4].

Group 1 - Tesla's 2025 shareholder meeting approved Elon Musk's $1 trillion compensation plan, with over 75% of shareholders in favor [4] - Tesla plans to mass-produce Cybercab by April 2026, targeting an annual capacity of 5 million units [4] - The price of chromium has shown a significant upward trend, with metal chromium priced at 79,060 RMB/ton as of November 7, 2025, reflecting a 2,020 RMB increase from October 31 [14] Group 2 - The automotive sector underperformed the Shanghai Composite Index from November 3 to November 7, 2025, with the automotive index down 1.2% [3] - Xpeng Motors announced the launch of three Robotaxi models in 2026, featuring high computing power and a vision-based approach [6] - The new generation of humanoid robots from Xpeng, named IRON, is set for mass production by the end of 2026, featuring advanced AI capabilities [6] Group 3 - The new materials sector is expected to experience rapid growth due to increasing demand and policy support, with a focus on electronic information, new energy, and biotechnology [42] - The new energy sector, particularly in storage, has seen significant developments, with over 100 million kilowatts of new storage capacity installed in China by the end of September 2025 [48] - The chemical industry is anticipated to enter a growth cycle, driven by reduced competition and increased demand for specific sectors [41]

Core Viewpoint - The company, Guoshengtang (02273.HK), has demonstrated resilience in the face of consumer pressure, showcasing steady growth as a leader in traditional Chinese medical services [1] Group 1: Share Buyback - On November 5, 2025, Guoshengtang announced a share buyback, spending HKD 13.2576 million to repurchase 467,800 shares [1] - The buyback price ranged from HKD 28.08 to HKD 28.62 per share [1] Group 2: Company Performance - Guoshengtang is positioned as a leader in the traditional Chinese medical services sector, highlighting its robust growth despite challenging consumer conditions [1]

Core Viewpoint - The company reported a total of approximately 1.607 million patient visits for the three months ending September 30, 2025, representing an increase of about 8.2% compared to the same period in 2024 [1] Company Summary - The total number of patient visits for the company reached approximately 1.607 million [1] - This figure indicates a growth rate of approximately 8.2% year-over-year [1]

Core Insights - The company, Guoshengtang (02273.HK), reported operational data for the three months ending September 30, 2025, indicating a total of approximately 1.607 million patient visits, which represents an increase of about 8.2% compared to the same period in 2024, where there were approximately 1.485 million patient visits [1] Summary by Category - **Operational Performance** - Total patient visits for the three months ending September 30, 2025, were approximately 1.607 million, reflecting an 8.2% growth year-over-year from approximately 1.485 million visits in 2024 [1]